Ultragenyx Pharmaceutical Inc
(LTS:0LIF)
$
51.134
0.686 (1.35%)
Market Cap: 4.70 Bil
Enterprise Value: 3.98 Bil
PE Ratio: 0
PB Ratio: 10.88
GF Score: 72/100 
Ultragenyx Pharmaceutical Inc at H C Wainwright Bioconnect Conference (Virtual) Transcript
Jan 13, 2022 / 12:00PM GMT
Release Date Price:
$82.77
Xiaodong Zhang
H.C. Wainwright & Co, LLC, Research Division - MD & Senior Healthcare Analyst
Hello, everyone. I'm Edwin Zhang a biotech analyst here at H.C. Wainwright. Welcome to our 2022 BioConnect Conference. It's my great pleasure to introduce Dr. Emil Kakkis, President and CEO of Ultragenyx. Welcome, Emil. Thanks for joining us.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director
Thanks for having me, Edwin.
Xiaodong Zhang
H.C. Wainwright & Co, LLC, Research Division - MD & Senior Healthcare Analyst
Maybe first, Emil, could you give us a quick overview about the company and then we will dive into the clinical programs.
Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director
Sure. Ultragenyx is a rare disease company now entering our 12th year since founding. And we have, in that time, gone to 4 approvals for 3 products and are global rare disease company. We have 6 programs in the clinic, including
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers